Registry-listed formulations

flupirtine · mesh:C034161

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

5 source entries across 3 studies. This list may not include all unresolved or historical entries.

  • flupirtineRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • 100 mg flupirtine intravenousRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Capsaicin + Flupirtine 0.5 µgRegistry intervention

    Molecular identity unconfirmed

    Separately studied ingredient; the full product remains distinct.

    View study and source
  • Capsaicin + Flupirtine 1.2 µgRegistry intervention

    Molecular identity unconfirmed

    Separately studied ingredient; the full product remains distinct.

    View study and source
  • Capsaicin + Flupirtine 3.0 µgRegistry intervention

    Molecular identity unconfirmed

    Separately studied ingredient; the full product remains distinct.

    View study and source

Success Metrics

Clinical Success Rate
50.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(25%)

Phase Distribution

Early Phase 1
1
25%
Phase 1
2
50%
Phase 2
1
25%

Phase Distribution

3

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Early Phase 1First-in-human
1(25.0%)
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
1(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(3)
Terminated(1)

Detailed Status

Completed3
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (25.0%)
Phase 12 (50.0%)
Phase 21 (25.0%)

Trials by Status

terminated125%
completed375%

Recent Activity

Clinical Trials (4)

Drug Details

Intervention Type
Drug
Molecule Type
Small molecule
Total Trials
4

External References

Names & Codes

Trade Names

Katadolon

ATC Classification

Research Codes

D 9998W-2964